Please try another search
Kahira Pharmaceuticals & Chemical Industries Company reported earnings results for the nine months ended March 31, 2024. For the nine months, the company reported sales was EGP 1,045.11 million compared to EGP 665.55 million a year ago. Net income was EGP 195.07 million compared to EGP 56.05 million a year ago. Basic earnings per share from continuing operations was EGP 13.06 compared to EGP 3.75 a year ago.
Period Ending: | Sep 30, 2023 | Jun 30, 2023 | Sep 30, 2022 | Jun 30, 2022 |
---|---|---|---|---|
Total Revenue | 335.32 | 339.69 | 245.45 | |
Gross Profit | 111.22 | 105.53 | 61.16 | |
Operating Income | 80.29 | 57.26 | 13.76 | |
Net Income | 59.17 | 41.04 | 14.71 |
Period Ending: | Sep 30, 2023 | Jun 30, 2023 | Sep 30, 2022 | Jun 30, 2022 |
---|---|---|---|---|
Total Assets | 1291.46 | 1261.27 | 1168.89 | |
Total Liabilities | 545.83 | 574.81 | 374.95 | |
Total Equity | 745.64 | 686.46 | 793.94 |
Period Ending: | Sep 30, 2023 | Jun 30, 2023 | Sep 30, 2022 | Jun 30, 2022 |
---|---|---|---|---|
Period Length: | 0 Months | 0 Months | 0 Months | 0 Months |
Cash From Operating Activities | 29.8 | 74.83 | 45.73 | |
Cash From Investing Activities | -15.21 | -12.51 | 4.21 | |
Cash From Financing Activities | 67.5 | -16.24 | -4.59 | |
Net Change in Cash | 82.1 | 46.07 | -31.3 | 45.36 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review